RANI · Rani Therapeutics Holdings, Inc.
$0.80
0.00 (-0.23%)
At close · Aug 14
Market Cap
$110.97M
Shares
139.40M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.80
Open$0.78
Day$0.77–0.82
52W close$0.46–2.85
Avg vol 30d923K
Short int8.5M · 6.1% float · 6.9d
Short vol43%
Last earningsMar 26, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Mar 23, 2027
Est · unconfirmed
· in 31 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
+3%
above
RSI (14)
52
neutral
MACD trend
Negative
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
−38%
trailing
YTD return
−41%
this year
Relative strength
−52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +10 funds added
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Falling
6.07% of float · ▼ -4.4% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
67 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+59%
Y/Y
EPS growth
+57%
Y/Y
Free cash flow
$-18.8M
Balance sheet
$18.6M
net cash
Quant / Vol
risk profile
Volatility
273%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
+3%
Bullish
RSI (14)
52
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-12% holders QoQ · +10 funds added
Insider flow
Accumulating
Net +$50.0K over 90 days · 0% sells
Short interest
Falling
6.07% of float · ▼ -4.4% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
67 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 14%
Range high $3
vs 200-day avg -32%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RANI
this stock
Rani Therapeutics Holdings, Inc.
|
$110.97M | -41.0% | +58.9% | — | 6.1% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RANI | +0.5% | +14.2% | -37.8% | +2.8% | -41.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.1% | +9.8% | -51.6% | -1.1% | -54.9% |
Key facts
CIK
1856725
CUSIP
753018100
13F (30d)
67 filings
64 filers
Visit website
Investor relations